How to Buy Axsome Therapeutics Stock
Axsome Therapeutics Inc
Axsome Therapeutics, Inc. , a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States.
Axsome Therapeutics stock last closed at $71.71, up 0.27% from the previous day, and has increased 2.28% in one year. It has overperformed other stocks in the Biotechnology industry by 0.24 percentage points. Axsome Therapeutics stock is currently +30.33% from its 52-week low of $55.02, and -27.12% from its 52-week high of $98.40.
At the moment, there are 47.37M shares of AXSM outstanding. The market cap of AXSM is $3.40B. In the last 24 hours, 271,993 AXSM shares were traded.
How to Buy Axsome Therapeutics Stock
Not sure how to invest in Axsome Therapeutics stock? Here's how.
- Choose where to buy Axsome Therapeutics stock: You need to pick an online brokerage, but don't worry - we've analyzed dozens of online brokerages and apps to help you choose where to buy Axsome Therapeutics stock.
- Open your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
- Put funds into your investment account: Pick your method of payment and add your details.
- Evaluate Axsome Therapeutics stock: The Axsome Therapeutics ticker symbol is AXSM. Is Axsome Therapeutics stock a good investment? Should you buy shares of AXSM? How do AXSM's underlying business fundamentals look? Do top analysts think Axsome Therapeutics is a good buy? Why has AXSM's stock price moved recently? (Hint: Our stock analysis website can help you evaluate if AXSM is a good stock to buy).
- Make your AXSM purchase: Decide if you will purchase AXSM shares at the current market price or use a limit order to buy AXSM shares at a particular price.
- Monitor your AXSM investment: Create a watchlist to keep track of your investment in Axsome Therapeutics stock.
Step 1: Choose where to buy Axsome Therapeutics stock
You will need an online brokerage account to access the NASDAQ market and buy AXSM stock.
Our recommended brokerage: eToro
We believe that eToro is the best online stock brokerage. Here's why:
- You can invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
- Access to world markets: From Technology to Industrials, New York to Tokyo — you can fill your portfolio with stocks from the globe's top exchanges.
- Social investing: eToro offers a community with more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of stock by signing up for an account with eToro now.
Open eToro AccountStep 2: Open your brokerage account
Now that you've selected your brokerage, the next step is to fill out some personal information so you can invest in AXSM stock today.
How to Set Up a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal data to start a new brokerage account.
- Submit your details by clicking the "Create Account" button. Get started with eToro today
Step 3: Put funds into your investment account
Now that you have opened your account on the highest rated stock app, you need to deposit funds:
Check out this video walkthrough to see the process of transferring funds into your new investment account.
Step 4: Evaluate Axsome Therapeutics stock
Once you have identified the best place to buy Axsome Therapeutics stock, it's critical to analyze their stock before you buy, so you can understand the risk and upside.
Axsome Therapeutics quick stats
AXSM Due Diligence Checks
WallStreetZen was built to help everyday investors do better fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on AXSM's stock page.
Is AXSM stock overvalued?
You can use many financial metrics, analyses, models, and charts to gauge AXSM's fair value.
Using relative valuations ratios:
- AXSM may be overvalued based on its P/B ratio of 17.79x, relative to Biotechnology industry P/B ratio of 5.85x
You can do additional valuation research on AXSM's stock here.
Is AXSM a healthy company?
Positive Health Checks:
- There are more short-term assets than long-term liabilities on the AXSM balance sheet.
- Total AXSM debt is lower than 5 years ago, relative to shareholder equity.
- There are more short-term assets than short-term liabilities on the AXSM balance sheet.
- AXSM has $386.19M in cash and short term investments. This is sufficient to cover its annual cash burn of $145.66M.
- AXSM has cash burn of 145662000. It has enough cash and short-term investments to cover this for at least one year.
Negative Health Checks:
- AXSM has a relatively high debt to equity ratio of 2.08.
- AXSM profit margin has gone up by 2.86 percentage points in the past year, but the company is still unprofitable.
Do analysts think it's a good time to buy Axsome Therapeutics stock
Out of 10 Wall Street analysts who give forecasts on AXSM, the consensus analyst rating on Axsome Therapeutics is a Strong Buy
It's important to keep in mind that analyst ratings are not stock recommendations, nor are they investment advice.
Most Recent AXSM Analyst Upgrades/Downgrades
David Hoang, a bottom 12% analyst from Citigroup maintains AXSM with a strong buy rating and raises their AXSM price target from $125.00 to $127.00, on Mar 26, 2024.
Joel Beatty, a top 24% analyst from Baird initiates coverage on AXSM with a buy rating and announces their AXSM price target of $108.00, on Mar 19, 2024.
Yatin Suneja, a bottom 14% analyst from Guggenheim maintains AXSM with a strong buy rating and raises their AXSM price target from $110.00 to $125.00, on Feb 21, 2024.
Guggenheim's Yatin Suneja raised their price target on Axsome Therapeutics (NASDAQ: AXSM) by 13.6% from $110 to $125 on 2024/02/21. The analyst maintained their Strong Buy rating on the stock.
In an assessment of Axsome Therapeutics' Q4 and FY 2023 print, released on 2024/02/20, Suneja predicted that Auvelity® sales will continue to beat Street expectations.
The analyst also expressed optimism about the potential of the company's AXS-05 and AXS-12 products to treat, respectively, ADA (Alzheimer's Disease Agitation) and narcolepsy.
Earnings Report
Axsome Therapeutics reported:
For Q4 2023:
- Loss per share of $0.73, which beat the Zacks Consensus Estimate of $(1.21) and, by 43%, Q4 2022’s $(1.28).
- Revenue of $71.5M, which beat the Zacks Consensus Estimate of $70M and, by 193%, Q4 2022’s $24.4M.
For FY 2023:
- Loss per share of $5.27, down 14.6% Y/Y.
- Revenue of $204.9M, up 309% Y/Y.
Management did not provide financial guidance in its press release or earnings call.
CEO Herriot Tabuteau commented: “2023 was a transformational year for Axsome, based on successful commercial execution as well as substantial pipeline advancement and expansion.
“During our first FY as a commercial company, Auvelity and Sunosi were prescribed for more than 100,000 patients combined.
“We expanded our Auvelity neuropsychiatry sales force and progressed our NDAs for AXS-07 in migraine and AXS-14 in fibromyalgia.
“We advanced our Phase 3 trials of AXS-12 in narcolepsy and AXS-05 in Alzheimer’s disease agitation, initiated a Phase 3 pivotal trial program for solriamfetol in ADHD, and announced three additional new indications for solriamfetol.
“We expect to continue the momentum in 2024 as we drive further growth for our two currently marketed products, and potentially submit two NDAs for migraine and fibromyalgia, read out three Phase 3 trials in narcolepsy, Alzheimer’s disease agitation, and ADHD, and, in the near term, initiate an equal number of new pivotal trials in depression, binge eating disorder, and shift work disorder.
“Enrollment in the SYMPHONY Phase 3 trial of AXS-12 in narcolepsy is now complete and we are on track to report topline results this quarter.”
Ashwani Verma, a top 33% analyst from UBS initiates coverage on AXSM with a strong buy rating and announces their AXSM price target of $111.00, on Feb 6, 2024.
David Amsellem, a top 25% analyst from Piper Sandler maintains AXSM with a strong buy rating and raises their AXSM price target from $90.00 to $113.00, on Jan 16, 2024.
You can dive deeper into what analysts are forecasting on the Axsome Therapeutics stock forecast page.
AXSM Technicals
Is AXSM Growing Revenue?
Last year, AXSM revenue was $270.60M. During the last one years, AXSM's revenue has increased by 440.8% per year. This was faster than the Biotechnology industry average of 28.56%.
Learn more about AXSM's earnings and revenue performance here.
Latest Insiders Trades at AXSM
In the past year, insiders at AXSM have sold more shares than they have bought.
Mark L. Jacobson, Chief Operating Officer of AXSM, was the latest AXSM insider to sell. They sold $1,904,942.20 worth of AXSM shares on Apr 1, 2024.
Learn more about who owns AXSM shares here.
Does AXSM stock generate passive income?
No, Axsome Therapeutics doesn't provide an income stream by paying out dividends.
AXSM Social Trading Data
One of the major reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other investors have to say.
Step 5: Make your AXSM purchase
There are two main types of orders:
- Market order: A market order is an order to buy or sell a stock at the best possible price.
Market orders are usually the best for newer investors. - Limit order: A limit order is an order to buy or sell a stock at a specific price (or better).
If you want to make sure you're buying or selling at a given dollar amount, use a limit order.
Hit the Open Trade button and your broker will execute your order.
If you require more info about investing in stocks on eToro, click the how to video below:
Step 6: Monitor your AXSM investment
Now that you own some shares in AXSM, you'll want to keep up with your new stock purchase.
Make a watchlist to keep tabs on your AXSM stock.
AXSM Feed
How to Buy Stock in Axsome Therapeutics
To reiterate, here are the 6 steps for buying Axsome Therapeutics stock:
- Choose where to buy Axsome Therapeutics stock
- Open your brokerage account
- Put funds into your investment account
- Evaluate Axsome Therapeutics stock
- Make your AXSM purchase
- Monitor your AXSM investment
If you require a brokerage, eToro is our favorite option.
Get Started with eToro TodayIf you would like to keep an eye on your investment in Axsome Therapeutics, add AXSM to your watchlist below.
More Stock Buying Guides You May Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.